The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of March 31, 2018:

• 40 negotiations are currently underway with 4 new files added since the last update of February 28, 2018:
  • Darzalex (daratumumab): Used to treat multiple myeloma
  • Fiasp (insulin aspart): Used to treat type 1 diabetes mellitus
  • Galafold (migalastat): Used to treat Fabry Disease
  • Pomalyst (pomalidomide): Used to treat multiple myeloma
•  207 joint negotiations have been completed with 2 new files added since the last update of February 28, 2018:
  • Glatect (glatiramer acetate): Used to treat relapsing-remitting multiple sclerosis
  • Zykadia (ceritinib): Used to treat ALK+ non-small cell lung cancer
• 58 drug products for which there were no negotiations, with 1 new file added since the last update of February 28, 2018:
  • Zinbryta (daclizumab beta): Used to treat multiple sclerosis
• 13 negotiations for brand name drug products have been recommended by the pCPA to be considered by each Province/Territory individually with no new files added since the last update of February 28, 2018.

For more information, please consult the pCPA’s website.